<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647592</url>
  </required_header>
  <id_info>
    <org_study_id>WECAN</org_study_id>
    <nct_id>NCT03647592</nct_id>
  </id_info>
  <brief_title>Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer</brief_title>
  <official_title>Real World Study to Evaluate the Efficacy and Resistant Mechanism of Erlotinib/Gefitinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with
      bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation,
      explore new drug resistance mechanisms under the A+T regimen and consistency between plasma
      and tissue detection driving genes, and finally assess the predictive value of plasma dynamic
      detection driving gene mutation profiles in predicting disease. The role of disease
      progression risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC)
      with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety
      of A+T regimen in the real world. Exploratory research contents are as follows: 1.
      Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the initial
      diagnosis; 2. Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the
      progression of A + T treatment; 3. New drug resistance mechanism of A + T treatment; 4.
      Plasma dynamics during A + T treatment. Detection (the first efficacy evaluation and a blood
      sampling before imaging PD) exploration and imaging progress sequence; 5. Plasma large panel
      dynamic drive gene mutation spectrum analysis to build disease progression risk model.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>Approximately 1 years</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Approximately 1 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Approximately 1 years</time_frame>
    <description>Disease control rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohorts 1</arm_group_label>
    <description>patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib/Gefitinib combined with Bevacizumab</intervention_name>
    <description>Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months</description>
    <arm_group_label>Cohorts 1</arm_group_label>
    <other_name>treatment of A+T</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue sample and plasma DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        30 non-saquamous non-small cell lung cancer with EGFR mutation positive (19del/L858R) were
        inrolled in this study.

        ECOG PS 0-1 All the patients recieved the treatment of erlotinib combined with Bevacizumab.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  EGFR mutation(19del/L858R)

          -  advanced non-saquamous non-small cell lung cancer

          -  primary treatment of first diagnosis

          -  performance statusï¼ˆ0-1)

        Exclusion Criteria:

          -  other genes mutation

          -  saquamous
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongchang Z MD, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>7+861383123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongchang Z MD, PhD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>+8613873123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Provincal Tumor Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Yang, MD</last_name>
      <phone>+86 731 89762323</phone>
      <email>yangnong0217@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Chunhua Zhou, MD</last_name>
      <phone>+86 731 89762321</phone>
      <email>zhouchunhua@hnszlyy.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nong Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Erlotinib/Gefitinib</keyword>
  <keyword>EGFR mutation positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

